The potential of NVP-BEZ235, a novel PI3K/mTOR inhibitor, as a single therapeutic agent has already been investigated in MYCN-amplified neuroblastoma, where it could be shown to exert both, an antiproliferative effect and a blockage of tumor angiogenesis [7]. This evidence concerns the gene MTOR and neuroblastoma.